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Hereditary bladder cancer
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Nijmegen, The Netherlands
Abstract
First degree relatives of patients with bladder cancer have a two-fold increased risk of bladder cancer but high-risk bladder
cancer families are extremely rare. There is no clear Mendelian inheritance pattern that can explain the increased familial
risk. This makes classical linkage studies for the mapping of susceptibility genes impossible. The disease is probably caused
by a combination of exposure to exogenous carcinogens and a large number of susceptibility genes with modest effects.
Genome-wide association studies are better suited to identify these genes. Three such studies are currently underway and
are expected to report their results in 2008.
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Introduction
The study of hereditary cancer syndromes such as
hereditary breast cancer and hereditary non-poly-
posis colorectal cancer has been very successful.
During the past two decades several high-penetrance
tumour suppressor genes and DNA repair genes
have been discovered which have had important
implications for clinical management and genetic
counselling. Among the urological cancers, prostate
and renal cell cancer are known to have hereditary
subtypes and susceptibility genes have been identi-
fied. In this article, the evidence for the existence of
a hereditary subtype of urinary bladder cancer is
reviewed.
Anecdotal evidence for an inherited subtype
The first indication for the existence of an inherited
subtype of bladder cancer comes from case reports.
Thelen and Schaeuble were the first to report
familial clustering of urothelial cell carcinoma
(UCC) in 1957, when they described identical
male twins with ‘‘benign transitional cell papillomas
of the bladder’’ [1]. Later, Fraumeni and Thomas
reported a family of Russian-Jewish origin with a
father (age at diagnosis 54 years) and three of his
sons (aged 57, 64 and 64) affected by bladder cancer
[2]. Benton and Henderson presented a 19-year-old
patient with bladder cancer whose father was diag-
nosed with bladder cancer 1 year before. Although
the son was occupationally exposed to glues and
solvents and the father was a welder, the early ages at
diagnosis argue against a pure exogenous cause [3].
A striking family was reported by McCullough et al.
in six members of a two-generation family. Four
affected patients were diagnosed before the age of
50 years, two before the age of 40. Two of the
patients later developed upper urinary tract UCC
and five had other tumours (basal cell, stomach,
prostate, cervix uteri and unknown primary). An
identical twin of one of the patients died of mela-
noma at the age of 63 years [4]. A germline mutation
in one of the unaffected parents of three affected
brothers seems likely in this extraordinary pedigree.
Several other case reports [58] also suggest but
cannot prove the existence of an inherited subtype of
bladder cancer. More formal evidence for familial
aggregation and segregation patterns must come
from epidemiological studies, while linkage studies
and/or modern molecular biology methods are
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needed for the mapping and identification of sus-
ceptibility genes.
Epidemiological evidence
Only a few epidemiological studies specifically ad-
dressed the issue of familial bladder cancer while
controlling for the number, age and smoking status
of family relatives. Kramer et al. collected demo-
graphic data and cigarette smoking status on all first
degree relatives of 319 men with bladder cancer
diagnosed in New York State and 319 neighbour-
hood controls [9]. The two cohorts of relatives were
then linked to the New York State Tumor Registry to
obtain valid data on cancer occurrence. Fourteen
cases of bladder cancer were found among 1619
relatives of patients, while seven were found among
1773 relatives of controls [adjusted hazard ratio
(HR) 1.9, 90% confidence interval (CI) 0.94.1].
Kiemeney et al. identified the first to third degree
relatives of 190 patients with bladder, ureter or renal
pelvis UCC diagnosed between 1983 and 1992 in
Iceland through the Icelandic Cancer Family Re-
source. The records of these 12 328 relatives were
subsequently linked to the 1965 to 1994 cancer
registry. In 41 of the 190 pedigrees at least one
relative had UCC of the urinary tract: observed to
expected (O/E) ratio 1.2 (95% CI 0.91.7). Surpris-
ingly, the O/E ratio was higher among second and
third degree relatives than among first degree
relatives, which argues against the existence of a
hereditary subtype of bladder UCC, at least in the
founder population of Iceland [10].
One of the largest studies has been conducted in
the Netherlands. Using a family casecontrol design,
1193 patients, newly diagnosed with UCC of the
bladder, ureter, renal pelvis or urethra, were con-
tacted. Information on the patients’ first degree
relatives was collected by postal questionnaires and
subsequent telephone calls. The patients’ partners
filled out a similar questionnaire on their relatives.
All reported occurrences of UCC among the 8014
first degree case-relatives and 5673 control-relatives
were verified using medical records. Among the
case-relatives, 101 individuals were diagnosed with
cancer of the bladder (n97), ureter (n3) and
renal pelvis (n1), compared with 38 individuals
among the control-relatives (bladder n36, ureter
n1 and urethra n1). In six case-families and two
control-families, two affected first degree relatives
were found. Overall, 8% of the patients had a
positive family history of UCC compared with 4%
of the controls. The mean age at diagnosis of
patients with a positive family history was similar
to that of patients with a negative family history (62
years). The mean age at diagnosis of UCC among
affected case-relatives was only slightly lower than
that of affected control-relatives (64 vs 66 years).
The cumulative risk of UCC among case-relatives
was 3.8% compared with 2.1% among control-
relatives. The age, gender and smoking-adjusted
random effect hazard ratio of UCC for case-relatives
compared with control-relatives was 1.8 (95% CI
1.32.7). This risk appeared to be higher among
women (HR3.2) and among non-smokers (HR
3.9), but stratification by probands with upper
versus lower urinary tract UCC, by probands with
a pTa versus pT1 tumour and by younger and
older probands did not suggest different results.
Also, there was no striking clustering of tumours at
other sites among all case-relatives. Among case-
relatives with a positive family history of UCC, there
was a non-significant clustering of tumours of the
female genital organs, non-UCC urinary tract tu-
mours and cancer of the haematolymphopoietic
system [11]. (See Box 1 for a summary of the
features of familial bladder cancer.)
Another large casecontrol study from Spain
among 1158 bladder cancer cases and 1244 controls
found an increased risk of bladder cancer by a factor
of 2.34 (95% CI 0.955.77) for those reporting a
positive family history of bladder cancer [12]. This
Box 1. Features of familial bladder cancer
(BlC) as assessed in the Dutch familial bladder
cancer study.
. Approximately 8% of patients with BlC have
a first degree relative with BlC.
. Less than 1% have two first degree relatives
with BlC.
. The risk of BlC cancer is increased by
around two-fold with one first degree rela-
tive with BlC.
. This risk may be somewhat higher among
women and among non-smokers.
. Increased risk is not due to familial correla-
tion of smoking.
. Increased risk is not very different for
relatives of pTa and pT1 cases.
. The age at diagnosis of patients with and
without a positive family history is not very
different.
. There is no strong familial clustering of BlC
with other types of cancer.
. The familial clustering cannot easily be
explained by a Mendelian inheritance pat-
tern.
Source: Aben et al. [11,17].
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familial risk was stronger, although not significantly
so, among NAT2 slow-acetylators and among those
with a GSTM1 non-null genotype. In this study, the
risk of bladder cancer was also increased with a
positive family history of oesophageal [odds ratio
(OR)2.7], lung (OR1.6), prostate (OR2.2)
and brain cancer (OR2.9) but there was no
verification of these cancer occurrences among
relatives.
Goldgar et al. [13] estimated O/E ratios in the
Utah Population Database by identifying all cases of
cancer in first degree relatives of patients. The first
degree relatives of bladder cancer probands were
found to have an increased risk of bladder cancer of
1.5 (95% CI 1.02.2) (not adjusted for smoking).
When only relatives of young probands (age B60
years) were considered, the familial risk was 5.1
(95% CI 1.012.5). Among these relatives of young
probands, a 3.7-fold increase (95% CI 1.17.4) in
the risk of lymphocytic leukaemia was found.
The cause of familial clustering
The epidemiological studies suggest that the risk of
bladder cancer is increased approximately two-fold
with a positive family history of bladder cancer, but
the cause of this clustering remains unclear. In a twin
study from Denmark, Sweden and Finland, Lich-
tenstein et al. reported a three- to four-fold higher
relative risk of bladder cancer among monozygotic
twins (6.6; 95% CI 2.616.9) than among dizygotic
twins (1.7; 95% CI 0.46.9). Assuming that the
correlation in environmental risk factors is similar
among monozygotic and dizygotic twins, this finding
suggests the existence of a genetic aetiology of
bladder cancer [14].
Dong and Hemminki [15] used the Swedish
Family-Cancer Database to quantify the risk of
cancer in more than 5.5 million offspring from
more than 2 million nuclear families where one of
the parents had cancer or one or more of the siblings
had cancer. The risk of bladder cancer for offspring
was increased by a factor of 1.5 (95% CI 1.12.0) if
one of the parents had bladder cancer. If one of the
siblings had bladder cancer, the risk was increased by
a factor of 3.3 (95% CI 1.75.8). The higher
(relative) risk in the case of an affected sibling was
considered to be an indication of a recessive or X-
linked transmission model. Because only one of the
12 offspring with bladder cancer who had an affected
sibling was female, the authors suggested that an X-
linked model was most likely [15]. However, ascer-
tainment bias due to cohort effects in, for example,
diagnostic procedures and data quality, may also
result in higher risks for siblings. The same holds for
a higher correlation in environmental exposures
between siblings compared with parents and off-
spring. With respect to the latter possibility, in a later
study on the Swedish Family-Cancer Database by
the same group, it was estimated that 7% of the
occurrence of bladder cancer is due to genetic
effects, 12% to shared environmental effects, 4% to
childhood environmental effects and 77% to non-
shared environmental effects [16].
The family casecontrol study from the Nether-
lands performed complex segregation analysis to
evaluate the segregation pattern of bladder cancer
within the 1193 families of probands with UCC.
Strong evidence for a Mendelian inheritance pattern
of UCC through a single major gene was not found.
The ‘‘no major gene’’ (or sporadic) model seemed to
be the most parsimonious one to describe the
occurrence of UCC in these families. However,
none of the Mendelian models could be clearly
rejected, which means that an inherited subtype of
UCC cannot be excluded. A major gene may
segregate in some families, but this effect may have
been masked by a background of high sporadic
incidence. In addition, the families consisted of first
degree relatives only, which make the power of
segregation analyses fairly limited, despite the large
number of families [17]. The same group also
evaluated whether mutagen sensitivity plays a role
in developing UCC and whether this sensitivity is
different in familial and non-familial cases. Intrinsic
susceptibility was quantified by a mutagen sensitivity
assay [mean number of chromatid breaks per cell
(PBLs) after damage induction with bleomycin in
the late S-G2 phase of the cell cycle]. UCC patients
showed a higher mutagen sensitivity score than
control subjects (mean number of chromatid breaks
per cell: 0.91, 95% CI 0.840.97, and 0.74, 95% CI
0.690.79, respectively; p0.001). Sporadic and
familial patients exhibited the highest susceptibility
(0.94, 95% CI 0.821.06, and 0.93, 95% CI 0.83
1.03, respectively). Hereditary patients (0.79, 95%
CI 0.720.86) showed a susceptibility similar to
controls [18]. From this study, it can be concluded
that mutagen sensitivity (i.e. genetic susceptibility)
increases the risk of non-hereditary UCC. The
relatively low mutagen sensitivity score among her-
editary patients may point to a different carcinogenic
pathway.
Recently, Kiemeney et al. [19] performed high-
density array comparative genomic hybridization
(CGH) studies in probands from 10 families sug-
gestive of hereditary bladder cancer. In all probands
large-scale copy number variations were detected, 41
in total, but all variations were already known as
polymorphisms.
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High-penetrance bladder cancer susceptibility
genes
Quite a few genes are known to increase modestly
the risk of bladder cancer (reviewed elsewhere in this
issue). Only two ‘‘high-penetrance’’ genes are known
so far: RB1 and CDC91L1.
RB1
Chan and Pratt described the family of an 11-year-
old white girl with bilateral retinoblastoma and
multiple non-radiation-induced osteosarcomas
[20]. The mother had unilateral retinoblastoma.
The maternal grandfather and one of his brothers
were diagnosed with bladder UCC at the ages of 60
and 47 years, respectively. Aherne described a family
with retinoblastoma and osteosarcoma in which the
mother of two affected children had bladder cancer
at the age of 40 years [21]. He also summarized five
other British cases of retinoblastoma. The father of
one patient died of bladder cancer at the age of 50.
Three relatively small cohort studies in the 1980s
confirmed the increased risk of bladder cancer
among relatives of retinoblastoma patients [2224].
This increased risk appeared to be confined to
known carriers of the mutated retinoblastoma gene.
Because the protein encoded by the retinoblastoma 1
gene, p105 Rb, functions in cell proliferation, DNA
replication, DNA repair and cell-cycle checkpoint
control, and because RB1 mutations are frequently
found in bladder tumours, it is possible that heredi-
tary retinoblastoma survivors run an increased risk
of bladder cancer. Recently, in a long-term follow-up
study from the UK, five bladder cancer cases were
found among 144 hereditary retinoblastoma cases,
an O/E ratio of 26.3 (95% CI 8.561.4) [25]. This
study shows that hereditary retinoblastoma patients
should also be checked for bladder cancer during
lifetime follow-up. Case reports also suggest the
occurrence of leiomyosarcomas of the bladder
among retinoblastoma survivors [2628].
CDC91L1
A new bladder cancer gene was discovered by a
research group from Baltimore [29]. In 1996, the
Baltimore group identified a family in which a male
was diagnosed with grade 2 superficial UCC of the
bladder at the age of 29 years. He subsequently
developed renal pelvis UCC. His mother died of
metastatic UCC of the bladder at the age of 65.
Because both the proband’s wife and his mother had
a history of miscarriages, a karyogram was made
which showed a balanced germline translocation
t(5;20)(p15;q11) [30]. The group zoomed in at the
breakpoints of this translocation, resulting in the
discovery of a new bladder cancer gene at 20q11
[29]. This gene, CDC91L1 encoding CDC91L1,
also called phosphatidylinositol glycan class U (PIG-
U), has a role in the glycosylphosphatidylinositol
(GPI) anchoring pathway. The authors suggested
that the gene is amplified and overexpressed in as
many as one-third of bladder cancers and primary
tumours, indicating that CDC91L1 should be re-
garded as an oncogene. The translocation led to
overexpression of the gene and, probably, to both
bladder cancers in this pedigree. Carriers of the
translocation in this family were therefore genetically
susceptible for bladder cancer. Because the exact
translocation site should be regarded as an extremely
rare phenomenon, this gene should not be consid-
ered as a candidate for the genetic cause of many
patients with hereditary bladder cancer. In addition,
the frequent overexpression in bladder tumours was
not confirmed in a study from the Netherlands [31].
Thus, the exact role of CDC91L1 has yet to be
established.
Screening in families with bladder cancer
The cumulative risks for a 50-year-old man and
woman of developing (non-pTa) bladder cancer
before the age of 60 are approximately 0.25% (1 in
400) and 0.07% (1 in 1400), respectively. For male
and female 40-year-olds, the risks of developing non-
pTa bladder cancer within the next 10 years are
0.06% (1 in 1600) and 0.02% (1 in 5000). In cases
with one first degree relative with bladder cancer,
these risks are doubled [11]. The absolute risk of
bladder cancer for a person with a positive family
history is therefore still very small, and probably not
a reason for screening. There are too few data to
deduce the absolute risk of bladder cancer for people
with two first degree relatives with bladder cancer (or
one first and one second degree relative in either the
paternal or maternal lineage). There are also no data
supporting the efficacy of screening unaffected
relatives of (at least) two patients. Nevertheless, it
seems logical to offer a routine check-up for such
relatives. The protocol for such a screening may be:
. starting at the age of 40, or 5 years earlier than
the age of the youngest patient in the family
. ultrasonography of the bladder and upper
urinary tract at the first screening only
. sediment and cytology once every year (possibly
including a marker such as NMP22).
Conclusions
A large number of case reports suggest that UCC of
the bladder clusters in families. Epidemiological
Hereditary bladder cancer 113
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studies have shown that the risk of bladder cancer is
increased approximately two-fold in case of a posi-
tive family history. The cause of this familial
clustering is still subject to speculation but several
lines of evidence suggest a contributing genetic
factor. This genetic factor is rare but its penetrance
may be quite high, although not as high as in, for
example, hereditary breast, prostate or colorectal
cancer. The effect of the genetic factor is probably
site specific: there is not a strong clustering of other
types of cancers in bladder cancer families. The
study of hereditary forms of common cancers has
yielded important clues about the aetiology and
pathogenesis of both inherited and sporadic forms
of these tumours. It has also led to possibilities for
genetic testing, early detection and even primary
prevention of cancer, as in the case of colorectal
cancer and breast cancer. A worldwide collaborative
effort to identify and study high-risk bladder cancer
families may move the field forward. An alternative
approach is genome-wide association (GWA) studies
in a classical casecontrol design. Such studies have
recently resulted in very interesting results in other
cancer sites. Three GWA studies in bladder cancer
are currently underway and the results are expected
in 2008.
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